ライフサイエンスコーパス: nefazodone

1 pears to be efficacious for nonresponders to nefazodone, and nefazodone appears to be effective for C

2 In addition, trovafloxacin, nefazodone, and ritonavir were reported to be associated

3 RI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic antidepressants,

4 cacious for nonresponders to nefazodone, and nefazodone appears to be effective for CBASP nonresponde

5 cally related drug vilazodone, trazodone and nefazodone are allosteric ligands: trazodone and nefazod

6 when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline.

7 the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy gro

8 pped out of the study prematurely, 22 in the nefazodone group and 8 in the CBASP group.

9 factory response) was 48 percent in both the nefazodone group and in the psychotherapy group, as comp

10 Adverse events in the nefazodone group were consistent with the known side eff

11 Trazodone and nefazodone have long been used as antidepressants.

12 new-generation non-SSRI antidepressants (eg, nefazodone hydrochloride, mirtazapine, bupropion hydroch

13 zodone are allosteric ligands: trazodone and nefazodone inhibit uptake by and transport-associated cu

14 Nefazodone is a weaker serotonin and norepinephrine reup

15 der to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive

16 have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

17 lopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and v

18 response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of

19 etine, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianepti

20 , levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, tianepti

21 ater risks of hepatotoxicity are iproniazid, nefazodone, phenelzine, imipramine, amitriptyline, dulox

22 Trazodone and nefazodone rescued a folding-deficient variant of the se

23 e to CBASP and the switch from from CBASP to nefazodone resulted in clinically and statistically sign

24 Because nefazodone seems to cause severe hepatocellular injury i

25 mistries should be performed before starting nefazodone therapy and patients should be monitored regu

26 temporal onset of disease after the start of nefazodone therapy suggested severe hepatocellular injur

27 However, the switch to CBASP following nefazodone therapy was associated with significantly les

28 at sample revealed that both the switch from nefazodone to CBASP and the switch from from CBASP to ne

29 ts (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participant

30 The dosage of nefazodone was 100 to 600 mg/d; CBASP was provided twice

31 Nefazodone was administered for 14 to 28 weeks before th

32 The antidepressants trazodone and nefazodone were approved some 4 and 3 decades ago, respe